Chronic kidney disease patients complicated with hypertension
Conditions
Interventions
Administration of losartan 50mg and hydrochlorothiazide 12.5mg by a combination drug
Administration of losartan 50mg and amlodipine 2.5-5mg
Sponsors
Nagoya University CKD Clinical Cooperation System Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients treated with losartan 50-100mg two months or more at the informed consent acquisition, and systolic blood pressure over 140, or diastolic blood pressure over 90 mmHg 2.Patients whose urinary protein in dipstic test was plus minus or greater in 2 times or more within 1 year before the informed consent acquisition 3.Outpatients 4.Sex unquestioned 5.20 and over,less than 80 years old
Exclusion criteria
Exclusion criteria: 1. Patients whose serum creatinine was 2 mg/dL or greater within three months or patients whose eGFR were less than 30 mL/min/1.73 m2 before the informed consent acquisition 2. Patients whose hepatic function was over 3 times higher than normal upper limit within three months before the informed consent acquisition 3. Patients whose HbA1c was more than 8.0 within three months before the informed consent acquisition 4. Patients received hospitalizing by onset of cardiovascular disease, myocardial infarction, cerebral apoplexy, cardiac insufficiency within six months before the informed consent acquisition 5. Patients complicated angina pectoris, cardiac insufficiency with NYHA 3 or greater at the informed consent acquisition 6. Patients who is already prescribed diuretic or Ca antagonist at the informed consent acquisition 7. Patients with poor feeding 8. Patients of remarkable emaciation 9. Patients complicated with nephrotic syndrome 10. Patients judged unsuitable by physician in charge
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| A. Following parameters from 0 to 3 months between 2 groups; 1. Systolic and diastolic blood pressure 2. BNP 3. HOMA-beta and HOMA-IR 4. hs-CRP 5. eGFR 6. Urinnary sodium excretion 7. Serum K 8. HbA1c 9. Serum uric acid 10.Pulse wave velocity(PWV):optional B. Following parameters from 0 to 6 months between 2 groups; 1. Urinary albumin excretionin 2. Serum K 3. HbA1c 4. Serum urin acid | — |
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin excretion from 0 to 3 months between 2 groups | — |
Countries
Japan
Contacts
Public ContactYoshinari Yasuda
Nagoya University, Graduate School of Medicine Department of Nephrology
Outcome results
None listed